Intravenous Infusions Plc has notified its shareholders and the general investing public that the Securities and Exchange Commission (SEC) has granted the company an extension of time to submit and file its full year 2025 audited financial statements.
In a public notice dated March 26, 2026, the Koforidua-based pharmaceutical manufacturer said the new deadline for submission of the full year 2025 financial statements is April 30, 2026. No reason for the extension was provided in the regulatory disclosure.
The notice was signed by Eugenia Bulley, General Manager for Finance and Administration at Intravenous Infusions Plc. The company, which has been in operation since 1969 and trades on the Ghana Stock Exchange (GSE) under the ticker IIL, specialises in the manufacture and marketing of intravenous infusions and small volume injectables for therapeutic use in Ghana and across the West African sub-region.
The company had earlier released unaudited results for the year ended December 31, 2025, showing a steep revenue contraction compared to 2024.
